Whole-genome profiling of chromosomal aberrations in hepatoblastoma using high-density single-nucleotide polymorphism genotyping microarrays

Cancer Science

Volumn 99, Issue 3, 2008, Pages 564-570

  Suzuki, Makoto ^a,c   Kato, Motohiro ^b   Yuyan, Chen ^b   Takita, Junko ^b   Sanada, Masashi ^b   Nannya, Yasuhito ^b   Yamamoto, Go ^b   Takahashi, Atsushi ^a   Ikeda, Hitoshi ^c   Kuwano, Hiroyuki ^a   Ogawa, Seishi ^b   Hayashi, Yasuhide ^d  

^a GUNMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d Gumna Children S Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME PROTEIN; H19 PROTEIN; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 2; CHROMOSOME 20; CHROMOSOME 2Q; CHROMOSOME 4Q; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENOTYPE; HEPATOBLASTOMA; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; METHYLATION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY;

EID: 38949099684     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00710.x     Document Type: Article

References (45)

1. Roebuck DJ, Perilongo G. Hepatoblastoma: An oncological review. Pediatr Radiol 2006; 36: 183-6.
2. Tiao GM, Bobey N, Allen S et al. The current management of hepatoblastoma: A combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr 2005; 146: 204-11.
3. Schnater JM, Kohler SE, Lamers WH, von Schweinitz D, Aronson DC. Where do we stand with hepatoblastoma? A review. Cancer 2003; 98: 668-78.
4. Ikeda H, Matsuyama S, Tanimura M. Association between hepatoblastoma and very low birth weight: A trend or a chance? J Pediatr 1997; 130: 557-60.
5. Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet 1992; 43: 1023-5.
6. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998; 132: 398-400.
7. Fukuzawa R, Hata J, Hayashi Y, Ikeda H, Reeve AE. Beckwith-Wiedemann syndrome-associated hepatoblastoma: Wnt signal activation occurs later in tumorigenesis in patients with 11p15.5 uniparental disomy. Pediatr Dev Pathol 2003; 6: 299-306.
8. Little MH, Thomson DB, Hayward NK, Smith PJ. Loss of alleles on the short arm of chromosome 11 in a hepatoblastoma from a child with Beckwith-Wiedemann syndrome. Hum Genet 1988; 79: 186-9.
9. Albrecht S, von Schweinitz D, Waha A, Kraus JA, von Deimling A, Pietsch T. Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res 1994; 54: 5041-4.
10. Oda H, Imai Y, Nakatsuru Y, Hata J, Ishikawa T. Somatic mutations of the APC gene in sporadic hepatoblastomas. Cancer Res 1996; 56: 3320-3.
11. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-9.
12. Yeh YA, Rao PH, Cigna CT, Middlesworth W, Lefkowitch JH, Murty VV. Trisomy 1q, 2, and 20 in a case of hepatoblastoma: Possible significance of 2q35-q37 and 1q12-q21 rearrangements. Cancer Genet Cytogenet 2000; 123: 140-3.
13. Nagata T, Mugishima H, Shichino H et al. Karyotypic analyses of hepatoblastoma. Report of two cases and review of the literature suggesting chromosomal loci responsible for the pathogenesis of this disease. Cancer Genet Cytogenet 1999; 114: 42-50.
14. Sainati L, Leszl A, Stella M et al. Cytogenetic analysis of hepatoblastoma: Hypothesis of cytogenetic evolution in such tumors and results of a multicentric study. Cancer Genet Cytogenet 1998; 104: 39-44.
15. Tonk VS, Wilson KS, Timmons CF, Schneider NR. Trisomy 2, trisomy 20, and del (17p) as sole chromosomal abnormalities in three cases of hepatoblastoma. Genes Chromosomes Cancer 1994; 11: 199-202.
16. Park JP, Ornvold KT, Brown AM, Mohandas TK. Trisomy 2 and 19, and tetrasomy 1q and 14 in hepatoblastoma. Cancer Genet Cytogenet 1999; 115: 86-7.
17. Balogh E, Swanton S, Kiss C, Jakab ZS, Secker-Walker LM, Olah E. Fluorescence in situ hybridization reveals trisomy 2q by insertion into 9p in hepatoblastoma. Cancer Genet Cytogenet 1998; 102: 148-50.
18. Sainati L, Leszl A, Surace C, Perilongo G, Rocchi M, Basso G. Fluorescence in situ hybridization improves cytogenetic results in the analysis of hepatoblastoma. Cancer Genet Cytogenet 2002; 134: 18-20.
19. Surace C, Leszl A, Perilongo G, Rocchi M, Basso G, Sainati L. Fluorescent in situ hybridization (FISH) reveals frequent and recurrent numerical and structural abnormalities in hepatoblastoma with no informative karyotype. Med Pediatr Oncol 2002; 39: 536-9.
20. Parada LA, Limon J, Iliszko M et al. Cytogenetics of hepatoblastoma: further characterization of 1q rearrangements by fluorescence in situ hybridization: An international collaborative study. Med Pediatr Oncol 2000; 34: 165-70.
21. Hu J, Wills M, Baker BA, Perlman EJ. Comparative genomic hybridization analysis of hepatoblastomas. Genes Chromosomes Cancer 2000; 27: 196-201.
22. Weber RG, Pietsch T, von Schweinitz D, Lichter P. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 2000; 157: 571-8.
23. Janne PA, Li C, Zhao X et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 2004; 23: 2716-26.
24. Huang J, Wei W, Zhang J et al. Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genomics 2004; 1: 287-99.
25. Peiffer DA, Le JM, Steemers FJ et al. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res 2006; 16: 1136-48.
26. Zhao X, Li C, Paez JG et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004; 64: 3060-71.
27. Nannya Y, Sanada M, Nakazaki K et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005; 65: 6071-9.
28. Yamamoto G, Nannya Y, Kato M et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007; 81: 114-26.
29. Wong KK, Tsang YT, Shen J et al. Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SNP) array with whole genome amplified DNA. Nucleic Acids Res 2004; 32: E69.
30. Trask BJ. Fluorescence in situ hybridization: Applications in cytogenetics and gene mapping. Trends Genet 1991; 7: 149-54.
31. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6.
32. Li LC, Dahiya R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics 2002; 18: 1427-31.
33. Koch A, Waha A, Hartmann W et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 2005; 11: 4295-304.
34. Douglass EC, Green AA, Hayes FA, Etcubanas E, Horowitz M, Wilimas JA. Chromosome 1 abnormalities: A common feature of pediatric solid tumors. J Natl Cancer Inst 1985; 75: 51-4.
35. Kaneko Y, Variakojis D, Kluskens L, Rowley JD. Lymphoblastic lymphoma: cytogenetic, pathologic, and immunologic studies. Int J Cancer 1982; 30: 273-9.
36. Kaneko Y, Kondo K, Rowley JD, Moohr JW, Maurer HS. Further chromosome studies on Wilms' tumor cells of patients without aniridia. Cancer Genet Cytogenet 1983; 10: 191-7.
37. Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myklebost O, Mandahl N. Amplification of chromosome 1 sequences in lipomatous tumors and other sarcomas. Int J Cancer 2004; 109: 363-9.
38. Kissil JL, Kimchi A. Assignment of death associated protein 3 (DAP3) to human chromosome 1q21 by in situ hybridization. Cytogenet Cell Genet 1997; 77: 252.
39. Turc-Carel C, Lizard-Nacol S, Justrabo E, Favrot M, Philip T, Tabone E. Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 1986; 19: 361-2.
40. Wong N, Lai P, Lee SW et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999; 154: 37-43.
41. Bando K, Nagai H, Matsumoto S et al. Identification of a 1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1999; 25: 284-9.
42. Koufos A, Hansen MF, Copeland NG, Jenkins NA, Lampkin BC, Cavenee WK. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 1985; 316: 330-4.
43. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000; 405: 486-9.
44. Zhang Y, Shields T, Crenshaw T, Hao Y, Moulton T, Tycko B. Imprinting of human H19: Allele-specific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching. Am J Hum Genet 1993; 53: 113-24.
45. Weksberg R, Nishikawa J, Caluseriu O et al. Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Hum Mol Genet 2001; 10: 2989-3000.